ISSN (Print): 1568-0266
ISSN (Online): 1873-4294
Volume 18, 32 Issues, 2018
Download PDF Flyer
Open Access Funding
ISSN (Print): 1568-0266
ISSN (Online): 1873-4294
Aims & Scope
Science Citation Index ExpandedTM, Journal Citation Reports/Science Edition, Index to Scientific Reviews®, Biochemistry & Biophysics Citation IndexTM, Current Contents®, BIOSIS, BIOSIS Previews, BIOSIS Reviews Reports and Meetings, ISI Alerting Services, MEDLINE/PubMed/Index Medicus, Scopus, EMBASE/Excerpta Medica, Chemical Abstracts Service/SciFinder, ProQuest, ChemWeb, Google Scholar, PubsHub, Index Copernicus, Genamics JournalSeek, MediaFinder®-Standard Periodical Directory, J-Gate, CNKI Scholar, Suweco CZ, TOC Premier, EBSCO, Ulrich's Periodicals Directory and JournalTOCs.
Ranking and Category:
Allen B. Reitz Fox Chase Chemical Diversity Center, Inc. Doylestown, PA USA
View Full Editorial Board
5 - Year: 2.994
Order Your Article Before Print
Self Archiving Policies
Instructions for Authors
Free Copies Online
Open Access Articles
Most Cited Articles
Advertise With Us
Most Accessed Articles
Most Popular Articles
Special Issue Submission
Selected Heterocyclic Compounds as Antioxidants. Synthesis and Biological Evaluation, 2014 :14(22); 2462 - 2477
E. Tsolaki, P. Nobelos, A. Geronikaki and E.A. Rekka
Rights and Permissions
Submit Abstract via Email
It has been a wonderful experience publishing our research paper with Bentham Science Publishers, who is very prompt and professional in providing excellent services. Due to this very reason, I would like to publish my forthcoming research results in the Bentham Science Publication “Current Topics in Medicinal Chemistry”.
S.K Srivastava (The Medicinal Chemistry Department, CSIR-CIMAP, Lucknow (U.P), , India)
Has contributed: QSAR Guided Semi-synthesis and In-Vitro Validation of Anticancer Activity in Ursolic Acid Derivatives
3 Abstract Ahead of Print are available electronically
5 Articles Ahead of Print are available electronically
At present, with the continuous development of bioinformatics, computing
technology has been successfully applied in all aspects of pharmacy and
medicine. Among them, the identification of drug-target interactions, synergistic
drug combinations and drug repositioning based on heterogeneous biological
data and powerful computational models are important topics in computational
biology. Research on these important issues is not only for a better
understanding of the various interactions and biological processes, but also for
the development of new drugs and the improvement of human drugs.
Previously, drug research faced an important problem that was difficult to
solve. Since multiple targets usually involve the same disease, following a single disease, a single target, a single drug paradigm
does not have the desired effect on accelerating drug discovery. Recently, in order to improve drug efficacy and overcome
problems before drug resistance, the development of multi-target drugs has received much attention. It is well known that despite
drug-target interactions, experimental assays for synergistic drug combinations and drug repositioning are very valuable
and have made significant contributions to drug research, but the technical challenges make these experiments time consuming,
expensive and limited to small scale studies.
Surprisingly, computational methods can provide new predictions for experimental scientists and narrow the scope of candidates
to accelerate drug discovery. Therefore, the development of a powerful method for the effective detection of potential
drug-target interactions in a genome-wide manner, synergistic drug combinations and drug-disease associations is urgent. Using
these computational models to obtain potential predictions with higher scores, and implementing biological experiments to verify,
will greatly reduce human and material resources.
The following pages of this issue are seven papers presenting current application of computational techniques in pharmacy and
medicine, representing only a small portion of current research. The following is a brief description of these papers.
In the opening paper of this issue, Muhammad et al. comprehensively presented the latest advances in drug target interaction
identification methods and their use in drug multi-pharmacology .
In the second review, Ding et al. summarized the latest advances in computational methods for predicting effective drug
combinations in a number of ways, including various datasets for discovering synergistic drug combinations, feature-based
similarity measures and machine learning methods, as well as web-based methods that reveal synergistic drug combinations. In
addition, the calculation method for predicting effective drug combinations was analyzed and predicted in this article .
Zhang et al. discussed current knowledge about ncRNA and network pharmacology-regulated genes involved in pulmonary
arterial hypertension, as well as potential drug targets for pulmonary arterial hypertension .
Zhang et al. comprehensively reviewed the drug toxicity prediction studies based on machine learning in recent years, and
compared the performance of the models proposed in these studies in terms of accuracy, sensitivity and specificity, providing
the current state-of-the-art in this field and highlighting the issues in the current studies .
Wang et al. outlined the structure-based drug design used in drug discovery and highlighted its recent successes and major
challenges of the current structure-based drug design approach .
Hao et al. summarized common methods for using protein-protein interaction networks to aid disease research and drug
discovery, including network topology analysis, identification of new pathways, drug targets, and subnetwork biomarkers for
Dong et al. discussed in detail the progress of parallel acceleration molecular docking software based on different common
high performance computing platforms. Not only is the existing suitable program optimized and ported to the high performance
computing platform, but many novel parallel algorithms are also designed and implemented. In addition, this article focuses on
the techniques and methods used to parallelize docking software and recommended exemplar case studies .
We would like to express our sincere gratitude to all authors and reviewers for their contribution to this issue. We would
also like to extend our appreciation to the Editor-in-Chief, Dr. Allen B. Reitz and the editorial staff of Current Topics in Medicinal
Chemistry for their excellent support and providing us with the opportunity to pursue this hot topic issue.
Enabling technologies like Computational Chemistry, Bioinformatics, Combinatorial Chemistry,
Metabolomics, Proteomics (OMICS in general), etc., are expected to speed up the discovery of more
efficient and safer drugs in Medicinal Chemistry. Recently, this journal has launched a series of special
issues focused on this topic. The title of this series of special issues is: New experimental and computational
tools for drug discovery: From chemistry to biology. Four (1-4) special issues are currently
available. In these issues, experts from around the world discuss the state-of-art and/or report new
methodologies. The methodologies focus on organic synthesis of new lead compounds, the in silico
screening of new lead compounds, computational discovery of drugs from natural compounds isolated
from plants, the repurposing of known drugs, re-engineering of cost-effective medicines, nano-systems
for drug release, etc. The present issue is entitled: New experimental and computational tools for drug
discovery: From chemistry to biology. Part 4. Metabolomics, Pharmacokinetics, and Medicinal Chemistry. Part 4 is the continuation
of the series and provides six papers focused on new technologies used in drug discovery, but this time with emphasis
on Metabolomics, Pharmacokinetics, and Medicinal Chemistry. The papers included in Part 4 can be summarized as follows:
Gross et al.,  point out that metabolomics experiments generate a rich array of complex high-dimensional data. They
suggest that this may, in part, account for past and more recent incomplete replications of previously specified biomarker panels,
especially if not adequately considered. Herein, they identify common impediments challenging the analysis of raw, targeted
Metabolomic abundance data and review methods that may remedy these issues, based on personal experiences and those
of others. In doing so, they propose an analytical pipeline suitable for the pre-processing of data prior to downstream biomarker
González-Domínguez et al.,  present work focused on intervention and observational trials as complementary tools in
Metabolomics. The authors provide a review of the literature regarding the application of metabolomics in assessing metabolic
alterations with diabetes, diabetic insulin resistance, and provide an oral glucose tolerance test case study to demonstrate the
complementarity of observational and interventional study designs.
Kataria et al.,  presented a work on the role of morin in Neurodegenerative Diseases (NDDs). NDDs are known to cause
profound effects on families and patients, and a tremendous financial burden on the healthcare system of most populations
worldwide. Morin, being a super antioxidant compound, may help prevent and mitigate such disorders by suppression of Reactive
Oxygen Species (ROS) and through the inhibition of multiple additional targets. In this review, the authors discuss various
neuropathological conditions and their specific target sites that may be relevant to morin’s neurobiological mechanisms.
Bueso-Bordils et al.,  focused on obtaining microbiological and pharmacokinetic predictive equations. They reviewed the
state-of-art in the area and also reported a new study. Multi-Linear Regression (MLR) analysis was carried out in order to accurately
predict physicochemical properties and biological activities on a group of antibacterial quinolones by means of a set of
structural descriptors called topological indices. The aim of this work included developing prediction equations for such properties,
after reviewing the relevant literature on antibacterial quinolones.
De Sousa Eduardo et al.,  focus on the requirement of research related to new antimicrobial agents, as increasing numbers
of microorganisms expressing antibiotic-resistance are emerging. In this paper, the authors review the topic and also pro- De Sousa Eduardo et al.,  focus on the requirement of research related to new antimicrobial agents, as increasing numbers
of microorganisms expressing antibiotic-resistance are emerging. In this paper, the authors review the topic and also provide
verification for the activity of a phytoconstituent against Escherichia coli strains ATCC 25922 and Staphylococcus aureus
ATCC 25923. The authors recommend further investigations, utilizing different methodologies assessing whether (+) - α-
pinene may provide an effective compound in future antimicrobial therapy.
Srivastava et al.,  focused on the inhibition of biofilm and virulence factors associated with Candida albicans by the partially
purified secondary metabolites of Streptomyces chrestomyceticus strain ADP4. Despite several advancements in antifungal
drug discovery, fungal diseases, such as Invasive Candidiasis (IC), remain associated with inordinately high rates of morbidity
and mortality worldwide. In this paper, chemical profiling indicates that ADP4 secondary metabolites contained potentially
beneficial alkaloids, flavonoids, polyphenols, terpenoids and triterpenes. The authors also report other experimental and
Infectious diseases are still one of the main cause of mortality and morbidity worldwide. In addition,
antimicrobial resistance is a well-recognized global threat; hence, necessitates the development of
tough policies to control the spread of disease-causing microorganisms coupled with antimicrobial
stewardship strategies and new therapies to reverse this process. In order to fight against microbial
infections, we need new antimicrobials. Much effort has been infused by the scientific community in
the past to the search of new and potential antimicrobials. Researchers have explored antimicrobials
based on plants, microorganisms, and even synthesized new compounds. This issue deals with the important
developments related to the topic of antimicrobials, especially, plant-based antimicrobials,
β-lactamase inhibitors, new synthetic drugs, and also about the target based drug delivery system in
case of chemotherapeutic agents.
Singh et al. have discussed the importance of plant antimicrobials of the past decade (2007-2017). As plants are the major
contributors of vast number of compounds, the plants have remained the indispensable source of medicine, and thus plant based
antimicrobials are important to be considered. Most of these compounds are produced as secondary metabolites and their medicinal
properties may be beneficial for the human being also. The synthetic chemistry has offered various molecules but most
of these are directly or indirectly related to some plant source. In the current review, they have presented the plant-based antimicrobials
reported between 2007 to 2017. Genera where most of the researchers have concentrated during this period includes,
Thymus, Helichrysum, Quercus, Jatropha, Gnaphalium, Acalypha, and Lippia. Some other miscellaneous gene on which one or
two reports are available include, Conocarpus, Chamaesyce, Bucida, Boehmesia, Pancratium, Artemisia, and Cinnamosma .
Wang et al. emphasized the development of β-lactamase inhibitors as potential antimicrobial agents. Horizontal transfer of
the genes encoding metallo-β-lactamases (MBLs) among Gram-negative bacteria pathogens has led to the emergence of drugresistant
pathogens, which now represent a major threat to the human health. It is urgent to develop new antibiotic agents to
fight against antibiotic resistance. Metallo-β-lactamases (MBLs) are an important class of Zn(II)-dependent enzymes that can
hydrolyze almost all β-lactams and render bacteria resistant to antibiotics in the clinic. To date, there are no clinically available
MBL inhibitors although a large number of MBL inhibitors have been identified. In this review, they have highlighted the recent
developments in small-molecule MBL inhibitors in the past decade .
Kaur et al. synthesized and characterized a new series of diazenyl chalcones by combining the azo and chalcone moiety
together and evaluated them for antimicrobial and antioxidant potential. Some of the derivatives had shown high antimicrobial
and antioxidant activity as compared to the standard drugs and hence presented new lead compounds for the development of
novel antimicrobial agents .
Conventional chemotherapeutics lack the specificity and controllability, thus may annihilate healthy cells while attempting
to annihilate cancerous ones. Newly developed nano-drug delivery systems have shown promise in delivering anti-tumor agents
with enhanced stability, durability, and overall performance; especially when used along with targeting and triggering techniques.
Ahmed et al. traced back the history of chemotherapy, addressing the main challenges that have encouraged medical
researchers to seek a sanctuary in nanotechnological-based drug delivery systems that are grafted with appropriate targeting
techniques and drug release mechanisms. A special focus will be paid towards acoustically triggered liposomes encapsulating
As a whole, all these papers illustrate the versatility of this topic and highlight the importance of developing new prospection
tools to advance the discovery of new compounds.
I want to thank Bentham Science Publishers especially, the Editor in Chief Dr. Allen B. Reitz, who provided me the opportunity
to contribute this thematic issue on such a topic and also all the editorial members for their continued support and cohesive
interactions. I express my highest gratitude to all the contributing authors for their commitment, subject expertise, dedicated
work, healthy coordination and support to me throughout the issue. I would also like to pay special thanks to all the reviewers
for spending their valuable time on critical analysis of the manuscripts and providing valuable suggestions for further
refining the manuscripts. At last, I am also thankful to all our readers.
Infection or colonization, contrary to what many people think, does not
necessarily imply immediate damage to the host. From birth, beneficial microorganisms
coexist and develop within us for a long time. However, when
such organisms cause damage to the host body, an infectious disease with the
associated symptoms and pathology is contracted. From a clinical point of
view, a pathogen is any microorganism capable of developing as an infectious
disease; where differences in pathogenicity depend on virulence. Infectious
diseases caused by pathogenic microorganisms, such as bacteria, viruses,
parasites or fungi can spread, from person to person, directly or indirectly and
throughout a community.
The studies united in this issue demonstrate the efforts of research to combat such infections and reduce the social cost of
Antimicrobial resistance is a major global concern. Strains of Tuberculosis (TB) resistant to rifampicin and other drugs
challenge patient survival and public health. The World Health Organization (WHO)  has issued treatment guidelines for
drug-resistant tuberculosis since 1997, and last updated these guidelines in 2016 based on the assessments of patient data in
both published and unpublished studies. As the first choice for patients assailed by Multiple Drug Resistant Or Rifampicin Resistant
(MDR/RR) strains, WHO recommends a standardized treatment regimen of from 9 to 12 months. Mycobacteria are
characterized as slow-growing bacillus having a cell wall composed of highly lipophilic mycolic acids. The nature of this cell
wall is of most importance to the development of new candidates for anti-tuberculosis (anti-TB) drugs. Mycobacterium tuberculosis
is an intracellular pathogen highly adapted to its natural host: the human. Its cell wall, consisting mainly of mycolic acids,
forms a hydrophobic barrier that confers resistance to both desiccation and discoloration by alcohol or acid. In our review,
entitled Multi-Target Antitubercular Drugs, we reported the discovery of 3 classes of compounds that can simultaneously
interact with more than one target of Mycobacterium tuberculosis.
Increased incidences of Candida infection have augmented morbidity and mortality in the human population, particularly
among severely immunocompromised patients and those having a long stay in hospitals (nosocomial infections). Many virulence
factors and fitness attributes are reported to be associated with the pathogenicity of Candida sp . It can cause infections
ranging from easily treatable superficial type to life-threatening invasive infections. Additionally, it has the capability to infect
humans of all age groups. Indeed, overutilization of broad-spectrum antibiotics has further complicated the scenario by leading
to the emergence of less sensitive Candida strains, especially non-albicans. Despite our developed armamentarium, the diagnosis
and treatment of human fungal infections remain a challenge. The review of Dr. Srivastava and co-workers entitled Emerging
virulence, drug resistance and future anti-fungal drugs for Candida pathogens, focused on the prevalence of Candida
spp. as human pathogens with emerging resistance to existing anti-fungal drugs. Furthermore, factors and mechanisms contributing
to the pathogenicity of Candida spp. and the challenges being faced in combating the devastating infections associated
with these pathogens have been discussed. Also, pros and cons of the current and future anti-mycotic drugs have been analyzed.
Current study assesses the in-vitro antimicrobial activity of the crude extract of D. retusa (whole plant) and its derived fractions
against clinically isolated human pathogenic bacteria and fungi . In the manuscript Evaluation of In-Vitro Antimicrobial
Potential of Daphne retusa Hemsl. against Human Pathogenic Bacteria and Fungi, Dr. Nawab et al. studied D. retusa
as powder dried Extracted with methanol (E1). The study showed that D. retusa had a very good inhibitory action against different
bacterial and fungal strains. All of the extracts were active almost against every microorganism used in the study. E2 has
maximum percent inhibition against bacterial growth while E1 has maximum percent inhibition against fungal growth. Streptococcus
pneumonia was the most susceptible bacteria while among fungi, Gongronella butleri showed the highest susceptibility.
Onion (Allium cepa L.) and garlic (Allium sativum L.) extracts are traditionally used in many cultures as antimicrobial
agents. Nonetheless, there is still a dearth of scientific validation pertaining to the antibacterial and possible antibiotic potentiating
activity of these plants . In the work Onion and garlic extracts potentiates the efficacy of conventional antibiotics
against standard and clinical bacterial isolates of Dr. Mahomoodally and co-workers, decoction as traditionally used and
methanol, ethanol, ethyl acetate, and acetone extracts of onion and garlic were evaluated for their antibacterial activity against
15 bacterial strains (6 ATCC strains and 9 clinical isolates) using the broth microdilution method to establish the minimum inhibitory
concentration. The bacteriostatic and bactericidal actions were determined as compared to conventional antibiotics
(streptomycin and chloramphenicol). Fractional Inhibitory Concentration (FIC) was determined to establish any synergistic
interaction between the extracts and antibiotics using a modified checkerboard assay. The observed antibacterial activity might
be justified due to the presence of high concentration of phenolic compounds in the extracts. This study has provided an opportunity
to establish valuable baseline information on the antibiotic potentiating activity of onion and garlic, which can be further
exploited for the treatment and/or management of infectious diseases.
Some research has shown that Lippia pedunculosa Essential Oil (EOLP) has interesting biological activities. However, its
low water solubility is the main challenge in achieving its therapeutic potential . In this context, Cyclodextrins (CDs) have
been widely used in order to overcome this problem due to their capability to improve the physicochemical properties of drugs.
In this perspective, the main goal of the study of Dr. Menezes et al. entitled Physicochemical characterization and antinociceptive
effect of β -cyclodextrin/Lippia pedunculosa essential oil in mice was to investigate how the improvement in the
physicochemical properties of inclusion complexes (EOLP and β-CD) enhances the antinociceptive effect in mice.
We, the Guest-Editors, would like to express our gratitude to the authors who contributed to this special issue, reporting
investigations in various aspects of Perspectives on Infectious Diseases: Progress and Therapeutics.
The discovery that the members within a protein complex are not only found in close proximity but also talking to
each other has expedited development of both experimental and computational techniques, which are used for
studying protein-protein interactions (PPIs). The former provides information regarding the existence of the
interaction and it also helps on the identification of the interaction interface. In spite of emerging roles of PPIs as
novel drug targets for treatment of various crucial diseases over the past decade the field is still far from having a
holistic understanding of the mechanism of interaction. Therefore, experimental techniques should guide and/or
complement computational studies in order to develop efficient therapeutic molecules having higher affinity and
lower side effects. In this special issue, we aim to summarize recent experimental and computational techniques
used for studying PPIs as well as their possible application on selected biological problems of great significance in
an effort to development of novel drugs that target PPIs. Among many others NF-kB, NSP1, MDXM, GPCRS,
CD-40, BAFF-BAFF-L are some of the systems that have been revised.
Cyclic peptides and peptidomimetic molecules (modified peptides) play
critical roles in natural processes, and can also be synthesized for use as research
tools and therapeutics. Protein-Protein Interactions (PPIs) play central
roles in regulating almost all biological processes across organisms and the
central dogma of biology. Compared to small molecules and antibodies, peptides
are advantageous for targeting PPIs because they maintain conformational
flexibility, can be synthesized using relatively straightforward techniques
and are generally less expensive. However, linear peptides are limited
by poor stability and inefficient cell membrane permeability. On the other
hand, cyclic peptides offer improved metabolic stability, bioavailability and
selectivity compared to their linear counterparts; moreover, cyclic peptides are particularly useful for targeting PPIs because
they maintain these enhanced drug-like properties without compromising bioavailability, as often occurs with linear peptides.
Thus, the development of cyclic peptides and peptidomimetics is of great interest in medicinal chemistry, as evidenced by numerous
investigational and approved cyclic peptide pharmaceutical compounds.
This thematic issue is comprised of six strong papers authored by esteemed colleagues renowned for their work in the field
of medicinal chemistry. The overarching topics covered include cyclic peptides in natural and therapeutic settings, the design of
cyclic peptides, several approaches to synthesize cyclic peptides, and examples of cyclic peptides in biological systems. First,
Rubin and Qvit present the first comprehensive review, analysis and critique of backbone-cyclized peptides, discussing their
design, construction, development, and application. To address the construction of backbone-cyclized peptides, Rubin, Tal-
Gan, Gilon, and Qvit subsequently provide a detailed guide for the conversion of protein active regions into peptidomimetic
therapeutic leads – delineating the identification of PPI sites, the definition of bioactive pharmacophores and the use of backbone
cyclization and cycloscan techniques to develop lead compounds.
Next, Perez reviews additional approaches for design of peptidomimetics and discusses their core properties, while comparing
and contrasting the medicinal chemistry and biophysical approaches for discovery and development. Testa, Papini, Chorev
and Rovero extensively discuss approaches to synthesize cyclic peptides and peptidomimetics, including in depth analysis of
the chemistries required to perform ring closing metathesis, lactamization, copper-catalyzed azide alkyne cycloaddition, and
other cyclization reactions. Following this, Hillman, Nadraws and Bertucci delve into stapled peptides and focus on recent advances
in their use for targeting PPIs therapeutically.
Lastly, Mull, Harrington, Sanchez, and Tal-Gan present examples of cyclic peptides in biological systems through an analysis
of cyclic peptide scaffolds in signal transduction pathways across a spectrum of prokaryotic and eukaryotic organisms as
models for the discovery of novel and broadly applicable therapeutic lead compounds.
It was an honor to compile this timely issue. Thanks to the journal for providing the opportunity for our colleagues and us to
share our perspectives. We hope the readers find this material engaging and useful, and that it will inspire further inquiry and
Cancer metabolism is an emerging area of research that offers an opportunity to target specific
metabolic vulnerabilities of cancer cells. Cancer cells undergo oncogene-mediated metabolic
reprogramming in order to meet their energy demands. Cancer cells adapt to their
microenvironment and rewire their metabolism to rely heavily on anaerobic glycolysis, a
phenomenon known as the ’Warburg effect’. In addition, cancer cells get addicted to glutamine and also
up regulate fatty acid synthesis to support their survival and rapid proliferation. Recently, there has
been a resurgence of interest in targeting carbohydrate, amino acid, and fatty acid metabolic pathways for
treatment of cancer and overcoming drug resistance in chemotherapy. Other emerging concepts include
targeting mitochondrial metabolism for the treatment of cancer. The overarching theme of this issue is to
highlight the current application, advances, and emerging concepts in the field of cancer metabolism and
discuss the prospects of metabolic inhibitors as next generation cancer therapeutics. The issue will also
emphasize medicinal chemistry efforts aimed at developing small molecule inhibitors targeting aberrant
No Text Found
The term "alternative" is employed to describe the test method in association with the principles of
the 3Rs - Replacement, Reduction and Refinement. In accordance with this principle, an alternative
method can be used to replace animal testing, reduce the quantity of animals required for each assay,
or refine an animal testing method to minimize pain and suffering.
There are different platforms available to create alternative methods including in vitro models and
computer-based systems. A few elements may be considered in terms of safety when it comes to the
development of a new drug or biomaterial. First it is important to identify the chemical identity and
the composition, as well as chemical structure, impurities and functional groups, followed by the determination
of the physical chemical properties. As a next step, the kinetics aspects, e.g. absorption,
distribution, metabolism and excretion should be evaluated. The mode and /or mechanism of action or
adverse outcome pathways as well as the chemical and biological interaction must be determined. Finally, the responses found
in alternative assays can lead to a proper safety assessment for drugs and biomaterials without the need for animal experimentation.
Within this context, this thematic issue focused on alternative assays applied to replace animal testing in order to assess the
safety and biological activity of currently available and novel drugs and biomedical devices. The manuscript entitled "Epithelial
organotypic cultures: a viable method to address the mechanisms of carcinogenesis by epitheliotropic viruses" describes the
mechanism of carcinogenesis, a topic that was initially researched mainly in animal models.
In another context, some alternative methods have also been employed in biomaterials, as the authors of “Current Methods
Applied to Biomaterials – Characterization Approaches, Safety Assessment and Biological International Standards” extensively
described. This review shows that using alternative tests for biomaterials has almost replaced animal tests, following an actual
tendency. Finally, the last two manuscripts, “Validation cytotoxicity assay for lipophilic substances” and “Alternative methods
to animal studies for the evaluation of topical/transdermal drug delivery systems” are important both for medicine and cosmetics
formulation, as the authors showed the importance to characterize the lipophilic substances, even a difficult issue in cytotoxicity
assays, and the importance of permeation in cosmetics and medical products.
Overall this special issue has addressed aspects concerning alternative assays applied to replace animal testing in order to
assess the safety and biological activity of currently available and novel drugs and biomedical devices and contain materials
that follow the topics in trends and published worldwide. This issue shows balanced viewpoints of experts contributing to
minimize the use of animal tests, in an attempt to act as a primary reference for industrial, commercial and research perspective
in an extensive field of science.
Head and neck squamous carcinoma (HNSCC) is the sixth most common malignant cancer in the world and it is characterized
by a poor prognosis. In fact, the estimated survival rate is 5 years from diagnosis.
The prognosis of the disease is significantly related to the stage in which the disease is diagnosed. Moreover, the therapies
are too invasive and not very efficient, disfiguring and debilitating the survivor’s quality of life which is much compromised.
Nowadays, there is not a reliable and non-invasive method for early diagnosis of oral squamous cell carcinoma and the simple
visual examination of the oral cavity is characterized by low sensitivity and specificity, also because the early stages of oral
carcinogenesis are not associated with clear clinical abnormalities in a significant number of patients.
The current issue of “Current Topics in Medicinal Chemistry (CTMC)” is aimed at reviewing the actual knowledge regarding
the HNSCC in order to cover this field with a broad series of papers. The first review was prepared by an Italian team led
by Fatima Ardito, Giovanni Di Gioia, Mario Roberto Pellegrino and Lorenzo Lo Muzio. The authors describe the role of genistein
as a potential anticancer agent against HNSCC. The second contribution is from Linda L. Eastham, Candace M. Howard,
Premalatha Balachandran, David S. Pasco, and Pier Paolo Claudio. In this case, the authors review the role of dietary phytochemicals
as an alternative approach to prevent HNSCC. The third review, led by Riccardo Concu and Maria Natalia Dias-
Soeiro Cordeiro, deals with the role of the Cetuximab in the treatment of HNSCC. The fourth contribution concerns the Aurora
kinase inhibitors in head and neck cancer; this work was prepared by a Chinese-Japanese team led by Guangying Qi, Jing Liu,
Sisi Mi, Takaaki Tsunematsu, Shengjian Jin, Wenhua Shao, Tian Liu, Naozumi Ishimaru, Bo Tang and Yasusei Kudo. Moving
on, Nicola Sgaramella and Karin Nylander review covers the topic of searching for new targets and treatments in the battle
against squamous cell carcinoma of the head and neck. Concu and Cordeiro present an innovative paper dealing with the development
of a new QSAR model aimed at the identification of new inhibitors for the epidermal growth factor receptor. Finally,
Ardito et al. present a new in vitro study of the inhibition activity of the curcumin against squamous cell carcinoma of tongue.